Benvitimod

Drug Profile

Benvitimod

Alternative Names: DHPS; GSK-2894512; WBI-1001

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Welichem Biotech
  • Developer Celestial Pharmaceuticals; Stiefel Laboratories; Welichem Biotech
  • Class Nonsteroidal anti-inflammatories; Resorcinols; Small molecules; Stilbenes
  • Mechanism of Action Cell movement inhibitors; Cytokine inhibitors; Phosphotransferase inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Psoriasis
  • Phase II Atopic dermatitis; Plaque psoriasis
  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 30 Jun 2017 GlaxoSmithKline plans a phase I trial for Psoriasis (In volunteers) (NCT03201978)
  • 30 Jun 2017 GlaxoSmithKline plans a phase III trial for Plaque psoriasis (NCT03202004)
  • 01 Jan 2017 GlaxoSmithKline completes a phase II trial in Atopic dermatitis (In adolescents, In adults, In Children) in USA, Japan and Canada (NCT02564055)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top